Vermillion develops a partnership with Johns Hopkins University
Vermillion develops a partnership with Johns Hopkins University on the development of novel biomarkers to detect ovarian, breast and prostate cancers.
2003
Vermillion receives a Department of Defense Idea Development Grant
Vermillion receives a Department of Defense Idea Development Grant that funds the discovery of biomarkers that later lead to the development of the first ovarian cancer diagnostic tool.
2005
Quest and Vermillion enter into a joint agreement
Quest and Vermillion enter into a joint agreement to accelerate the development and commercialization of Ova1
2005
Vermillion completes an initial public offering
Vermillion completes an initial public offering of its stock on the Nasdaq stock exchange, trading under the symbol VRML
2009
Ova1 is the first- ever proteomic in vitro diagnostic multivariate index assay to be approved by the FDA
Ova1 is the first- ever proteomic in vitro diagnostic multivariate index assay to be approved by the FDA for clinical use for the assessment of ovarian cancer malignancy risk in women with pelvic masses when a surgical response is planned. Ova1 has a Negative Predictive Value (NPV) of 91%.